Ramsay Generale de Sante (GDS) AI Stock Analysis

• Market Cap: €1.11B
• Dividend Yield: N/A
• Average Volume (3M): 264.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.04
• Revenue Growth: 5.79%
• EPS Growth: -575.58%
• Country: FR
• Employees: 34,218
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Care Facilities
• EPS (TTM): -0.72
• Shares Outstanding: 110,389,690
• 10 Day Avg. Volume: 424
• 30 Day Avg. Volume: 264
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €11.00
• Price Target Upside: 7.84% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 55 Neutral
• Price Target: €11.00 ▲(7.84% Upside)

The most significant factor affecting the overall score is financial performance, which shows mixed results with positive revenue growth but negative net income and high leverage. Technical analysis suggests neutral momentum, and valuation is challenged by negative earnings, making the stock less attractive. The absence of earnings call and corporate events data limits further analysis.

Ramsay Generale de Sante Business Overview & Revenue Model

Company Description

Ramsay Generale de Sante (GDS) is a leading private healthcare provider in France, operating a comprehensive network of hospitals and clinics. The company offers a wide range of medical services including surgery, oncology, obstetrics, rehabilitation, and mental health care. GDS is part of the Ramsay Health Care Group, a global healthcare organization, and is renowned for its commitment to quality care and patient safety.

How the Company Makes Money

Ramsay Generale de Sante generates revenue primarily through the provision of medical and healthcare services across its network of hospitals and clinics. The company charges patients or their insurance providers for treatments, procedures, and consultations. Additionally, GDS benefits from partnerships with public health agencies and contracts with private health insurers, ensuring a steady stream of income. Ancillary services such as diagnostics, laboratory tests, and pharmacy sales also contribute to the company's revenue. GDS's focus on efficiency and high-quality service delivery helps maintain its profitability in the competitive healthcare sector.

Ramsay Generale de Sante Financial Statement Overview

Summary

Ramsay Generale de Sante shows a mixed financial picture. Revenue growth is positive, but profitability has been impacted, leading to a negative net income. The balance sheet highlights high leverage, which could pose risks in managing liabilities. Cash flow generation remains a strength, providing some stability despite profit challenges.

Income Statement

The income statement shows mixed performance. Revenue has grown steadily from $4.02B in 2021 to $5.14B TTM, with a recent growth rate of 2.74% compared to the previous annual period. However, net income has turned negative in the TTM period, indicating profitability challenges. EBIT and EBITDA margins have declined, reflecting operational inefficiencies or increased costs.

Balance Sheet

The balance sheet reveals high leverage with a debt-to-equity ratio of 3.48 in the TTM period, indicating significant reliance on borrowed funds. Stockholders' equity has decreased, and the equity ratio stands at 17.37%, suggesting limited equity buffer against liabilities. The return on equity has turned negative due to the net loss, highlighting concerns about current profitability.

Cash Flow

Cash flow analysis shows some strengths, with positive free cash flow of $440M in TTM and a 5.19% growth from the previous period. The operating cash flow to net income ratio is robust due to strong cash flow generation despite a net loss. However, the free cash flow to net income ratio highlights the pressure on profitability.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	5.14B	5.01B	4.70B	4.30B	4.02B	3.75B
Gross Profit	1.41B	3.94B	3.72B	3.41B	3.20B	3.01B
EBITDA	535.50M	591.30M	656.30M	691.00M	604.00M	543.80M
Net Income	-79.70M	-53.90M	49.40M	118.40M	65.00M	18.70M
Balance Sheet
Total Assets	6.49B	6.90B	6.96B	6.79B	6.68B	6.71B
Cash, Cash Equivalents and Short-Term Investments	157.80M	381.30M	362.90M	143.50M	620.00M	548.20M
Total Debt	3.92B	4.06B	4.15B	3.97B	3.85B	3.92B
Total Liabilities	5.33B	5.67B	5.68B	5.55B	5.58B	5.68B
Stockholders Equity	1.13B	1.19B	1.25B	1.21B	1.07B	1.01B
Cash Flow
Free Cash Flow	440.00M	418.30M	426.70M	68.90M	475.90M	560.90M
Operating Cash Flow	607.50M	586.80M	598.90M	262.50M	652.30M	729.60M
Investing Cash Flow	-164.20M	-180.50M	-175.40M	-471.10M	-181.40M	-186.20M
Financing Cash Flow	-470.30M	-401.50M	-197.10M	-264.20M	-390.60M	-377.20M

Ramsay Generale de Sante Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 10.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:GDS, the sentiment is Negative. The current price of 10.2 is below the 20-day moving average (MA) of 10.54, below the 50-day MA of 10.81, and below the 200-day MA of 10.89, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 33.08 is Neutral, neither overbought nor oversold. The STOCH value of 35.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:GDS.

Ramsay Generale de Sante Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VETO	73 Outperform	€882.23M	14.99	10.64%	1.19%	1.88%	5.79%
LNA	70 Outperform	€319.90M	14.39	7.12%	4.23%	9.58%	-6.69%
VIRP	63 Neutral	€2.76B	18.96	14.95%	0.44%	12.07%	20.48%
CLARI	57 Neutral	€1.61B	―	-1.70%	―	1.98%	85.87%
GDS	55 Neutral	€1.11B	―	-6.74%	―	5.79%	-575.58%
Sector *	54 Neutral	€4.18B	13.09	-41.26%	2.55%	14.43%	-26.74%
EMEIS	51 Neutral	€2.16B	0.02	-22.82%	―	8.43%	-102.06%